blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3029069

EP3029069 - ANTI-HUMAN CD26 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.08.2020
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  30.08.2019
FormerGrant of patent is intended
Status updated on  29.04.2019
FormerExamination is in progress
Status updated on  01.06.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Juntendo Educational Foundation
2-1-1, Hongo
Bunkyo-ku
Tokyo 113-8421 / JP
[2016/23]
Inventor(s)01 / MORIMOTO, Chikao
c/o Juntendo University
2-1-1 Hongo
Bunkyo-ku
Tokyo 113-8421 / JP
02 / HATANO, Ryo
c/o Juntendo University
2-1-1 Hongo
Bunkyo-ku
Tokyo 113-8421 / JP
03 / YAMADA, Taketo
2-1-26 Takaido Higashi
Suginami-ku
Tokyo 168-0072 / JP
04 / OHNUMA, Kei
c/o Juntendo University
2-1-1 Hongo
Bunkyo-ku
Tokyo 113-8421 / JP
 [2016/23]
Representative(s)Blodig, Wolfgang
Wächtershäuser & Hartz
Patentanwaltspartnerschaft mbB
Weinstrasse 8
80333 München / DE
[2016/23]
Application number, filing date14831681.330.07.2014
[2016/23]
WO2014JP70084
Priority number, dateJP2013015853331.07.2013         Original published format: JP 2013158533
[2016/23]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015016267
Date:05.02.2015
Language:JA
[2015/05]
Type: A1 Application with search report 
No.:EP3029069
Date:08.06.2016
Language:EN
[2016/23]
Type: B1 Patent specification 
No.:EP3029069
Date:02.10.2019
Language:EN
[2019/40]
Search report(s)International search report - published on:JP05.02.2015
(Supplementary) European search report - dispatched on:EP05.12.2016
ClassificationIPC:C07K16/28, C07K16/40, C12N5/10, G01N33/53, G01N33/574, G01N33/577, C12N15/09, C12P21/08, G01N33/569, G01N33/564
[2017/01]
CPC:
C07K16/40 (EP,US); C07K16/2896 (EP,US); C12N5/163 (EP,US);
G01N33/564 (EP,US); G01N33/56972 (EP,US); G01N33/56983 (EP,US);
G01N33/573 (US); G01N33/574 (EP,US); G01N33/57419 (EP,US);
G01N33/57423 (EP,US); G01N33/57434 (EP,US); G01N33/577 (EP,US);
G01N33/6893 (EP,US); A61K2039/505 (US); C07K2317/24 (EP,US);
C07K2317/76 (US); G01N2333/70596 (EP,US); G01N2333/948 (US);
G01N2500/00 (EP,US); G01N2800/042 (EP,US) (-)
Former IPC [2016/23]C07K16/28, C07K16/40, C12N5/10, G01N33/53, G01N33/574, G01N33/577, C12N15/09, C12P21/08
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/23]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MONOKLONALER ANTI-HUMAN-CD26-ANTIKÖRPER ODER ANTIGENBINDENDES FRAGMENT DAVON[2016/23]
English:ANTI-HUMAN CD26 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF[2016/23]
French:ANTICORPS MONOCLONAL ANTI-CD26 HUMAIN, OU SON FRAGMENT DE LIAISON À L'ANTIGÈNE[2016/23]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase11.02.2016Translation filed 
11.02.2016National basic fee paid 
11.02.2016Search fee paid 
11.02.2016Designation fee(s) paid 
11.02.2016Examination fee paid 
Examination procedure11.02.2016Examination requested  [2016/23]
06.06.2017Amendment by applicant (claims and/or description)
05.06.2018Despatch of a communication from the examining division (Time limit: M04)
01.08.2018Reply to a communication from the examining division
30.04.2019Communication of intention to grant the patent
20.08.2019Fee for grant paid
20.08.2019Fee for publishing/printing paid
20.08.2019Receipt of the translation of the claim(s)
Opposition(s)03.07.2020No opposition filed within time limit [2020/37]
Fees paidRenewal fee
01.08.2016Renewal fee patent year 03
31.07.2017Renewal fee patent year 04
30.07.2018Renewal fee patent year 05
31.07.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.07.2014
AL02.10.2019
AT02.10.2019
CY02.10.2019
CZ02.10.2019
DK02.10.2019
EE02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
IT02.10.2019
LT02.10.2019
LV02.10.2019
MC02.10.2019
MK02.10.2019
MT02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
SI02.10.2019
SK02.10.2019
SM02.10.2019
TR02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
IS02.02.2020
PT03.02.2020
[2022/32]
Former [2022/27]HU30.07.2014
AL02.10.2019
AT02.10.2019
CY02.10.2019
CZ02.10.2019
DK02.10.2019
EE02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
IT02.10.2019
LT02.10.2019
LV02.10.2019
MC02.10.2019
MT02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
SI02.10.2019
SK02.10.2019
SM02.10.2019
TR02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
IS02.02.2020
PT03.02.2020
Former [2021/15]AL02.10.2019
AT02.10.2019
CZ02.10.2019
DK02.10.2019
EE02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
IT02.10.2019
LT02.10.2019
LV02.10.2019
MC02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
SI02.10.2019
SK02.10.2019
SM02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
IS02.02.2020
PT03.02.2020
Former [2020/51]AL02.10.2019
AT02.10.2019
CZ02.10.2019
DK02.10.2019
EE02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
IT02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
SI02.10.2019
SK02.10.2019
SM02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
IS02.02.2020
PT03.02.2020
Former [2020/38]AL02.10.2019
AT02.10.2019
CZ02.10.2019
DK02.10.2019
EE02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
IT02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
SK02.10.2019
SM02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
IS02.02.2020
PT03.02.2020
Former [2020/37]AL02.10.2019
AT02.10.2019
CZ02.10.2019
DK02.10.2019
EE02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
SK02.10.2019
SM02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
IS02.02.2020
PT03.02.2020
Former [2020/36]AL02.10.2019
AT02.10.2019
CZ02.10.2019
DK02.10.2019
EE02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
IS02.02.2020
PT03.02.2020
Former [2020/35]AL02.10.2019
AT02.10.2019
CZ02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
RO02.10.2019
RS02.10.2019
SE02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
PT03.02.2020
IS24.02.2020
Former [2020/32]AL02.10.2019
AT02.10.2019
CZ02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
RS02.10.2019
SE02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
PT03.02.2020
IS24.02.2020
Former [2020/25]AT02.10.2019
CZ02.10.2019
ES02.10.2019
FI02.10.2019
HR02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
RS02.10.2019
SE02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
PT03.02.2020
IS24.02.2020
Former [2020/24]AT02.10.2019
ES02.10.2019
FI02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
SE02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
PT03.02.2020
IS24.02.2020
Former [2020/23]AT02.10.2019
ES02.10.2019
FI02.10.2019
LT02.10.2019
LV02.10.2019
NL02.10.2019
PL02.10.2019
SE02.10.2019
BG02.01.2020
NO02.01.2020
GR03.01.2020
PT03.02.2020
Former [2020/22]FI02.10.2019
LT02.10.2019
NL02.10.2019
SE02.10.2019
BG02.01.2020
NO02.01.2020
PT03.02.2020
Former [2020/21]NL02.10.2019
NO02.01.2020
Former [2020/20]NL02.10.2019
Documents cited:Search[Y]WO2007014169  (Y S THERAPEUTICS INC [US], et al) [Y] 1-15 * examples 5-11; par. 248, 251-252 *;
 [XP]  - RYO HATANO ET AL, "Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue", DIAGNOSTIC PATHOLOGY, BIOMED CENTRAL LTD, LO, (20140206), vol. 9, no. 1, doi:10.1186/1746-1596-9-30, ISSN 1746-1596, page 30, XP021178896 [XP] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1186/1746-1596-9-30
 [Y]  - VISHWA AMATYA, "Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines", ONCOLOGY REPORTS, (20110905), vol. 26, doi:10.3892/or.2011.1449, ISSN 1021-335X, pages 1369 - 1375, XP055322123 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.3892/or.2011.1449
 [Y]  - OORD VAN DEN J J, "EXPRESSION OF CD26/DIPEPTIDYL-PEPTIDASE IV IN BENIGN AND MALIGNANT PIGMENT-CELL LESIONS OF THE SKIN", BRITISH JOURNAL OF DERMATOLOGY, OXFORD : WILEY-BLACKWELL, UK, (19980401), vol. 138, doi:10.1046/J.1365-2133.1998.02171.X, ISSN 0007-0963, pages 615 - 621, XP002944502 [Y] 1-15 * abstract; p. 615 *

DOI:   http://dx.doi.org/10.1046/j.1365-2133.1998.02171.x
International search[Y]JP2009502139  (Y'S THERAPEUTICS, CO., LTD.);
 [Y]  - DONG R-.P. ET AL., "Correlation of the epitopes defined by anti- CD 26 mAbs and CD 26 function", MOLECULAR IMMUNOLOGY, (1998), vol. 35, pages 13 - 21, XP055313946
 [Y]  - HUHN J. ET AL., "The Adenosine Deaminase-Binding Region Is Distinct from Major Anti- CD 26 mAb Epitopes on the Human Dipeptidyl Peptidase IV, (CD 26) Molecule", CELLULAR IMMUNOLOGY, (1999), vol. 192, pages 33 - 40, XP055313948
 [Y]  - ABBOTT C. A. ET AL., "Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted propeller domain", EUR. J. BIOCHEM, (1999), vol. 266, pages 798 - 810, XP055313950

DOI:   http://dx.doi.org/10.1046/j.1432-1327.1999.00902.x
 [Y]  - ULMER A. J. ET AL., "CD 26 Antigen is a Surface Dipeptidyl Peptidase IV (DPPIV) as Characterized by Monoclonal Antibodies Clone TII-19-4-7 and 4EL1C7", SCAND. J. IMMUNOL., (1990), vol. 31, pages 429 - 435, XP001048107
by applicantUS4816567
 US5565332
 US5580717
 US5733743
 US6265150
 WO02092127
 WO2007014169
 WO2008114876
    - FOX DA; HUSSEY RE; FITZGERALD KA ET AL., "Tal, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody", J IMMUNOL, (1984), vol. 133, pages 1250 - 1256
    - TANAKA T; CAMERINI D; SEED B ET AL., "Cloning and functional expression of the T cell activation antigen CD26", J IMMUNOL, (1992), vol. 149, pages 481 - 486, XP001038740
    - OHNUMA K; DANG NH; MORIMOTO C, "Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function", TRENDS IN IMMUNOLOGY, (2008), vol. 29, doi:doi:10.1016/j.it.2008.02.010, pages 295 - 301, XP022701231

DOI:   http://dx.doi.org/10.1016/j.it.2008.02.010
    - MORIMOTO C; SCHLOSSMAN SF, "The structure and function of CD26 in the T-cell immune response", IMMUNOL REV, (1998), vol. 161, pages 55 - 70
    - DANG NH; TORIMOTO Y; SUGITA K ET AL., "Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation", J IMMUNOL, (1990), vol. 145, pages 3963 - 3971
    - MASUYAMA J; YOSHIO T; SUZUKI K ET AL., "Characterization of the 4C8 antigen involved in transendothelial migration of CD26hi T cells after tight adhesion to human umbilical vein endothelial cell monolayers", J EXP MED, (1999), vol. 189, pages 979 - 990
    - OHNUMA K; INOUE H; UCHIYAMA M ET AL., "T-cell activation via CD26 and caveolin-1 in rheumatoid synovium", MOD RHEUMATOL, (2006), vol. 16, doi:doi:10.1007/s10165-005-0452-4, pages 3 - 13, XP019375207

DOI:   http://dx.doi.org/10.1007/s10165-005-0452-4
    - HATANO R; OHNUMA K; YAMAMOTO J; DANG NH; MORIMOTO C, "CD26-mediated co-stimulation in human CD8+ T cells provokes effector function via pro-inflammatory cytokine production", IMMUNOLOGY, (2013), vol. 138, doi:doi:10.1111/imm.12028, pages 165 - 172, XP055436603

DOI:   http://dx.doi.org/10.1111/imm.12028
    - HATANO R; OHNUMA K; YAMAMOTO J; DANG NH; YAMADA T; MORIMOTO C, "Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody", BR J HAEMATOL, (2013), vol. 162, pages 263 - 277
    - HAVRE PA; ABE M; URASAKI Y; OHNUMA K; MORIMOTO C; DANG NH, "The role of CD26/dipeptidyl peptidase IV in cancer", FRONT BIOSCI, (2008), vol. 13, pages 1634 - 1645
    - UMIO YAMAGUCHI ET AL., "Distinct Gene Expression-Defined Classes of Gastrointestinal Stromal Tumor", JOURNAL OF CLINICAL ONCOLOGY, (2008), vol. 26, no. 25, pages 4100 - 4108
    - INAMOTO T; YAMADA T; OHNUMA K ET AL., "Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors", CLIN CANCER RES, (2007), vol. 13, doi:doi:10.1158/1078-0432.CCR-07-0110, pages 4191 - 4200, XP008116674

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-0110
    - AOE K; AMATYA VJ; FUJIMOTO N ET AL., "CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma", CLIN CANCER RES, (2012), vol. 18, pages 1447 - 1456
    - AL-LAZIKANI ET AL., J. MOLEC. BIOL., (1997), vol. 273, pages 927 - 948
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495
    - TORIGOE T., "Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: usually high frequency of down-regulation in breast cancer tissue", PATHOLOGY INTERNATIONAL, (2012), vol. 62, pages 303 - 308
    - MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METHODS, (1992), vol. 24, pages 107 - 117
    - CARTER ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 163 - 167
    - STERNBERGER LA ET AL., "The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes", J HISTOCHEM CYTOCHEM, (1970), vol. 18, no. 5, pages 315 - 33, XP000672174
    - HSU SM; RAINE L; FANGER H, "Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures", J HISTOCHEM CYTOCHEM, (1981), vol. 29, no. 4, pages 577 - 80
    - GRAHAM RC JR; KARNOVSKY MJ, "The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique", J HISTOCHEM CYTOCHEM, (1966), vol. 14, no. 4, pages 291 - 302, XP009111547
    - DONG RP; TACHIBANA K; HEGEN M ET AL., "Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function", MOL IMMUNOL, (1998), vol. 35, pages 13 - 21, XP055313946
    - MORIMOTO C ET AL., "1F7, A novel cell surface molecule, involved in helper function of CD4 cells", J IMMUNOL, (1989), vol. 143, pages 3430 - 3439
    - TORIMOTO Y ET AL., "Biochemical characterization of CD26 (dipeptidyl peptidase IV): Functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies", MOLECULAR IMMUNOLOGY, (1992), vol. 29, no. 2, doi:doi:10.1016/0161-5890(92)90099-J, pages 183 - 192, XP023683117

DOI:   http://dx.doi.org/10.1016/0161-5890(92)90099-J
    - TANAKA T; DUKE-COHAN JS; KAMEOKA J ET AL., "Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV", PROC NATL ACAD SCI USA, (1994), vol. 91, doi:doi:10.1073/pnas.91.8.3082, pages 3082 - 3086, XP000579867

DOI:   http://dx.doi.org/10.1073/pnas.91.8.3082
    - TANAKA T; KAMEOKA J; YARON A; SCHLOSSMAN SF; MORIMOTO C, "The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1993), vol. 90, doi:doi:10.1073/pnas.90.10.4586, pages 4586 - 4590, XP002993053

DOI:   http://dx.doi.org/10.1073/pnas.90.10.4586
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.